Highlights•Safe past de-escalation treatments.•Surgery after complete response might be
overtreatment.•Biopsies might diagnose response.In patients with operable early breast …

Abstract The ninth St Gallen (Switzerland) expert consensus meeting in January 2005 made
a fundamental change in the algorithm for selection of adjuvant systemic therapy for early …

Objective: To determine the impact of tumor biology on rates of breast-conserving surgery
and pathologic complete response (pCR) after neoadjuvant chemotherapy. Background …

Neoadjuvant (primary systemic) treatment is the standard treatment for locally advanced
breast cancer and a standard option for primary operable disease. Because of new …

Introduction Tumor microenvironment immunity is associated with breast cancer outcome. A
high lymphocytic infiltration has been associated with response to neoadjuvant …

Purpose To evaluate whether hormonal receptor (HR) status can influence the prognostic
significance of pathologic complete response (pCR). Patients and Methods This …

Early randomized trials of the addition of neoadjuvant chemotherapy (NACT) to the
treatment regimen of patients with breast cancer failed to demonstrate an improvement in …

Neoadjuvant systemic chemotherapy is a possible therapeutic approach for the treatment of
locally advanced operable, primarily non-operable or inflammatory breast cancer …

Neoadjuvant (primary systemic) treatment has become a standard option for primary
operable disease for patients who are candidates for adjuvant systemic chemotherapy …

The international radiotherapy (RT) expert panel has revised and updated the RT guidelines
that were accepted in 2020 at the 4th Hungarian Breast Cancer Consensus Conference …